Actavis confirms generic Alzheimer’s patch patent challenge

Generics/News | Posted 22/03/2013 post-comment0 Post your comment

US generics maker Actavis (formerly Watson) confirmed on 8 March 2013 that it had filed with FDA an amendment to its abbreviated new drug application (ANDA) for rivastigmine transdermal system to include the 13.3 mg/24 hr dosage strength. Actavis’ product is a generic version of Novartis’ Exelon Patch, which is used to treat people with mild to moderate dementia associated with Alzheimer’s or Parkinson’s disease.

Exelon patch

Novartis filed suit against Watson on 7 March 2013 in the US District Court for the District of Delaware seeking to prevent Actavis from commercializing its 13.3 mg/24 hr strength product prior to the expiration of certain US patents, and resulting in a stay of final FDA approval of Watson’s 13.3 mg/24 hr strength generic for up to 30 months from the date that Novartis received notice of Actavis’ ANDA amendment filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

Actavis previously filed an ANDA with FDA seeking approval to market rivastigmine transdermal system patch 4.6 mg/24 hr and 9.5 mg/24 hr, and was subsequently sued by Novartis in November 2011. That application is subject to a separate 30-month stay.

Actavis (formerly Watson) believes it may be the first applicant to file an ANDA for the generic Exelon Patch and should its ANDA be approved, it may be entitled to 180 days of generics market exclusivity.

For the 12 months ending 31 January 2013, Exelon had US sales of approximately US$521 million according to IMS Health data.

Related articles

FDA approves generic opiate-dependency drugs

Watson becomes Actavis

Actavis launches generic valsartan in Europe

Permission granted to reproduce for personal and educational use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Actavis

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010